NovoCure Ltd (NVCR)
NovoCure Ltd (NVCR) from its SEC filings: 2025 revenue $655.4 million (+8% vs the year before), net margin -21%, free cash flow -$75.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Revenue (2025) | $655.4 million |
| Revenue growth | +8% |
| Net income | -$136.2 million |
| Net margin | -20.8% |
| Free cash flow | -$75.7 million |
| Diluted EPS | $-1.22 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +16% |
| Cash | $93.7 million |
| Long-term debt | $195.0 million |
| Share count, 1 year | +4% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.